Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases. Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients. The company's preclinical pipeline comprises mAbs targeting various bacterial and viral pathogens, including respiratory syncytial virus. Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ASNS
Previous Symbol
CUSIPN/A
Phone781-819-5704
Debt
Debt-to-Equity Ratio0.28
Current Ratio5.08
Quick Ratio5.08
Price-To-Earnings
Trailing P/E Ratio-0.24
Forward P/E Ratio-1.35
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$4.29 per share
Price / Book0.93
Profitability
EPS (Most Recent Fiscal Year)($16.23)
Net Income$-33,870,000.00
Net MarginsN/A
Return on Equity-103.84%
Return on Assets-70.75%
Miscellaneous
Employees40
Outstanding Shares14,310,000
Market Cap$51.11 million
OptionableNot Optionable
Arsanis (NASDAQ:ASNS) Frequently Asked Questions
What is Arsanis' stock symbol?
Arsanis trades on the NASDAQ under the ticker symbol "ASNS."
How were Arsanis' earnings last quarter?
Arsanis Inc (NASDAQ:ASNS) released its quarterly earnings data on Friday, November, 9th. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.74) by $0.02. View Arsanis' Earnings History.
When is Arsanis' next earnings date?
What price target have analysts set for ASNS?
4 brokers have issued 1 year price objectives for Arsanis' stock. Their forecasts range from $2.50 to $26.00. On average, they expect Arsanis' stock price to reach $14.25 in the next year. This suggests a possible upside of 272.1% from the stock's current price. View Analyst Price Targets for Arsanis.
What is the consensus analysts' recommendation for Arsanis?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arsanis in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Arsanis.
What are Wall Street analysts saying about Arsanis stock?
Here are some recent quotes from research analysts about Arsanis stock:
- 1. According to Zacks Investment Research, "Arsanis, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovering and developing monoclonal antibodies for the targeted immunotherapy of serious infections. The company's product pipeline includes ASN100, ASN200, ASN300, ASN400 and ASN500 which are in preclinical stage. It operates primarily in the United States and Austria. Arsanis, Inc. is based in Waltham, United States. " (11/14/2018)
- 2. Cantor Fitzgerald analysts commented, "As the company advances its pipeline toward commercialization, we expect catalysts to drive Arsanis’s stock higher. Valuation Summary We use a blend of EV/EBITDA and DCF analysis to arrive at our $26 12-month price target. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of EV/EBITDA and DCF analysis to arrive at our $26 12-month price target." (6/28/2018)
Has Arsanis been receiving favorable news coverage?
Media headlines about ASNS stock have been trending somewhat positive on Thursday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Arsanis earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next few days.
Are investors shorting Arsanis?
Arsanis saw a increase in short interest in the month of November. As of November 30th, there was short interest totalling 1,173,598 shares, an increase of 106.8% from the November 15th total of 567,470 shares. Based on an average daily volume of 8,343,897 shares, the short-interest ratio is presently 0.1 days. View Arsanis' Current Options Chain.
Who are some of Arsanis' key competitors?
Some companies that are related to Arsanis include Idera Pharmaceuticals (IDRA), Allena Pharmaceuticals (ALNA), Compugen (CGEN), Neon Therapeutics (NTGN), Erytech Pharma (ERYP), Jounce Therapeutics (JNCE), Organovo (ONVO), Fennec Pharmaceuticals (FENC), Nantkwest (NK), Champions Oncology (CSBR), Applied Genetic Technologies (AGTC), Pluristem Therapeutics (PSTI), Cidara Therapeutics (CDTX), Aptose Biosciences (APTO) and Aevi Genomic Medicine (GNMX).
Who are Arsanis' key executives?
Arsanis' management team includes the folowing people:
- Dr. Tillman U. Gerngross, Co-Founder & Chairman (Age 54)
- Dr. René Russo, Pres, CEO & Director (Age 43)
- Mr. Michael P. Gray MBA, CPA, COO & CFO (Age 47)
- Dr. Anthony Christopher Stevens, Chief Medical Officer (Age 59)
- Dr. Eszter Nagy, Co-Founder (Age 52)
When did Arsanis IPO?
(ASNS) raised $50 million in an initial public offering (IPO) on Thursday, November 16th 2017. The company issued 3,100,000 shares at $15.00-$17.00 per share. Citigroup, Cowen and Piper Jaffray served as the underwriters for the IPO.
Who are Arsanis' major shareholders?
Arsanis' stock is owned by a number of of retail and institutional investors. Top institutional investors include Alambic Investment Management L.P. (0.93%). Company insiders that own Arsanis stock include Polaris Venture Management Co and Tillman U Gerngross. View Institutional Ownership Trends for Arsanis.
Which institutional investors are buying Arsanis stock?
ASNS stock was bought by a variety of institutional investors in the last quarter, including Alambic Investment Management L.P.. Company insiders that have bought Arsanis stock in the last two years include Polaris Venture Management Co and Tillman U Gerngross. View Insider Buying and Selling for Arsanis.
How do I buy shares of Arsanis?
Shares of ASNS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arsanis' stock price today?
One share of ASNS stock can currently be purchased for approximately $3.83.
How big of a company is Arsanis?
Arsanis has a market capitalization of $51.11 million. The company earns $-33,870,000.00 in net income (profit) each year or ($16.23) on an earnings per share basis. Arsanis employs 40 workers across the globe.
What is Arsanis' official website?
How can I contact Arsanis?
Arsanis' mailing address is 890 WINTER STREET SUITE 230, WALTHAM MA, 02451. The company can be reached via phone at 781-819-5704 or via email at [email protected]
MarketBeat Community Rating for Arsanis (NASDAQ ASNS)
MarketBeat's community ratings are surveys of what our community members think about Arsanis and other stocks. Vote "Outperform" if you believe ASNS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASNS will underperform the S&P 500 over the long term. You may vote once every thirty days.
